Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 11/20 | 0.65 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | AURKA | O14965 | 4/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.42 |
| ▸ | PAK4 | O96013 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 3/20 | 0.42 |
| ▸ | LTK | P29376 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.42 |
| ▸ | CLK2 | P49760 | 3/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.42 |
| ▸ | MST1R | Q04912 | 3/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043340 | 0.90 | ZAP70 (0.68) | ZAP70JAK2SYKTYK2ABL1 | |
| SCHEMBL1048818 | 0.88 | ZAP70 (0.53) | ZAP70JAK2AURKADAPK3PAK4 | |
| SCHEMBL1050113 | 0.85 | ZAP70 (0.52) | ZAP70JAK2SYKPDGFRBPDGFRA | |
| SCHEMBL1050425 | 0.83 | ZAP70 (0.71) | ZAP70JAK2AURKADAPK3PAK4 | |
| SCHEMBL1048127 | 0.82 | ZAP70 (0.56) | ZAP70JAK2AURKADAPK3PAK4 | |
| SCHEMBL1043321 | 0.82 | ZAP70 (0.49) | ZAP70JAK2AURKADAPK3PAK4 | |
| SCHEMBL1047037 | 0.79 | ZAP70 (1.00) | ZAP70SYKBRD4CREBBP | |
| SCHEMBL1048841 | 0.79 | ZAP70 (0.49) | ZAP70JAK2AURKADAPK3PAK4 | |
| SCHEMBL1048726 | 0.79 | ZAP70 (0.80) | ZAP70JAK2SYKTYRO3 | |
| SCHEMBL1157920 | 0.79 | ZAP70 (0.63) | ZAP70KDRSYKBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885JAK2 63/4885AURKA 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.